Caliber Imaging & Diagnostics Receives Orders for VivaScope Systems From Chinese Distributor ConBio (Shanghai) Co. Print
Tuesday, 07 January 2014 02:00

ROCHESTER, N.Y. and BOSTON--Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., has received orders totaling $554,000 for VivaScope® systems from its Chinese distributor ConBio (Shanghai) Co., Ltd.

Orders totaling $188,000 shipped in the fourth quarter of 2013, with the remaining $366,000 scheduled to be shipped in the first quarter of 2014.

ConBio has been Caliber's exclusive distributor in China and Hong Kong for nearly five years.

Margaret Shang, CEO of ConBio, said, "To date, the VivaScope system has been adopted by many of our customers throughout China, primarily national and regional opinion leaders in dermatology, and additional customers are quickly following suit. With more than 60 VivaScope systems on the ground in China, the system's noninvasive point-of-care platform has proven to be clinically applicable in a wide range of contexts."

Ms. Shang continued, "Before the VivaScope system, dermatologists did not have any meaningful tools to give an objective and scientific evaluation and diagnosis of various skin conditions noninvasively in vivo at the cellular level. VivaScope has helped dermatologists in accurately diagnosing skin diseases, follow-up and evaluation of treatment, which has significantly helped Chinese doctors gain knowledge about various skin conditions and their patients' response to treatment."

L. Michael Hone, Chief Executive Officer of Caliber I.D., said, "The Chinese market represents a tremendous growth opportunity for us as we seek to expand the global reach of our VivaScope technology. Working closely with ConBio, we look forward to solidifying our relationships with the medical community in China, and increasing our global footprint in this growing market through 2014 and beyond."

Founded in Shanghai in 1996, ConBio (Shanghai) Co. Ltd. distributes advanced skin laser equipment to a variety of customers in China and abroad. The company maintains offices in several cities including Beijing, Shanghai, Guangzhou, Chengdu, Xian and


About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and

Error. Page cannot be displayed. Please contact your service provider for more details. (19)

research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and
pending patents worldwide, VivaScope significantly improves outcomes and reduces costs, allowing physicians to quickly detect cancerous lesions that appear benign. VivaScope dramatically reduces the need for expensive, painful and time-consuming biopsies. VivaScope also has significant applications in testing and analysis in the cosmetics industry. For more information about Caliber I.D. and its products, please visit

VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.

CONTACT: Richard Pulsifer          Chief Financial Officer          (617) 348-9821          Investor Relations:          Dian Griesel Int'l.          Cheryl Schneider          (212) 825-3210          Public Relations:          Dian Griesel Int'l.          Susan Forman or Laura Radocaj          (212) 825-3210

BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!